Clinical trials: Adhesiveness, open to volunteers
Idiopathic Parkinson Disease
Adhesion and Safety of Rotigexole Compared to Neupro®
A non-inferiority open-labelled crossover randomized controlled trial, of two arms, to investigate the adhesiveness and safety of Rotigexole 8 mg/24 hours transdermal patch, manufactured by Eva pharma, Egypt, compared to the…
- Trial name
- START (NCT07015346)
- Testing
- Rotigexole 8 mg, Neupro ® 8 mg
- Volunteers
- 40 people
- Sponsor
- Eva Pharma